Preview

The Clinician

Advanced search

SYSTEMIC VASCULITIS: NOVELTY IN CLASSIFICATION, DIAGNOSIS, AND TREATMENT

https://doi.org/10.17650/1818-8338-2015-9-2-8-12

Abstract

Systemic vasculitides (SV) are a heterogeneous group of acute and chronic diseases, the most important pathomorphological sign of which is inflammation and necrosis of the vascular wall. The basis for the classification of SV is their etiology and pathogenesis, the type of affected vessels and the pattern of inflammation, predominant organ involvements, clinical manifestations, a genetic predisposition, and demographic characteristics. To diagnose vasculitis is a difficult task due to a broad spectrum of its clinical manifestations that depend on the predominant size of affected vessels, the involved organs and systems, and the magnitude of the inflammatory process. There are no specific laboratory tests for most forms of SV; nonspecific inflammatory measures and activated autoimmune reactions are noted to be higher. Screening for SV determines the levels of anti-neutrophil cytoplasmic antibodies (ANCA), cryoglobulins, anti-glomerular basement membrane antibodies, and anti-complement C1q antibodies. However, biopsy with its specimen being pathomorphologically characterized, as well as current noninvasive or minimally invasive diagnostic techniques remain relevant because of a large number of seronegative variants of vasculitis. The ANCA-associated vasculitis management algorithm developed by the British Society of Rheumatology has been presented in 2015. The timely diagnosis and treatment at the onset of SV is the basis for quality of life and survival improvement. 

About the Authors

N. A. Shostak
Acad. A.I. Nesterov Department of Faculty Therapy, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; 1 Ostrovityanova St., Moscow, 117997, Russia
Russian Federation


A. A. Klimenko
Acad. A.I. Nesterov Department of Faculty Therapy, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; 1 Ostrovityanova St., Moscow, 117997, Russia
Russian Federation


References

1. Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1–11.

2. Nataraja A., Mukhtyar C., Hellmich B. et al. Outpatient assessment of systemic vasculitis. Best Pract Res Clin Rheumatol 2007;21:713–32.

3. Silva de Souza A.W. Autoantibodies in systemic vasculitis. Front Immunol 2015;6:184.

4. Rao D.A., Wei K., Merola J.F. et al. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing. J Rheumatol 2015;42(5): 847–52.

5. Diamantopoulos A.P., Haugeberg G., Hetland H. et al. Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res (Hoboken) 2014;66(1):113–9.

6. Klink T., Geiger J., Both M. et al. Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. Radiology 2014;273(3):844–52.

7. Puppo C., Massollo M., Paparo F. et al. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. Biomed Res Int 2014;2014:574248.

8. Prieto-González S., Arguis P., GarcíaMartínez A. et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 2012;71(7):1170–6.

9. Muratore F., Kermani T.A., Crowson C.S. et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 2015;54(3):463–70.

10. Ntatsaki E., Carruthers D., Chakravarty K. et al. BSR and BHPR guideline for the management of adults with ANCAassociated vasculitis. Rheumatology (Oxford). 2014;53(12):2306–9.

11. Hatemi G., Melikoglu M., Tunc R. et al. Apremilast for Behçet's syndrome -a phase 2, placebo-controlled study. N Engl J Med 2015;372(16):1510–8.


Review

For citations:


Shostak N.A., Klimenko A.A. SYSTEMIC VASCULITIS: NOVELTY IN CLASSIFICATION, DIAGNOSIS, AND TREATMENT. The Clinician. 2015;9(2):8-12. (In Russ.) https://doi.org/10.17650/1818-8338-2015-9-2-8-12

Views: 2155


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1818-8338 (Print)
ISSN 2412-8775 (Online)